drugset / Trial / NCT03118180
CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma
Phase 1/2
Unknown
50 enrolled
Zhejiang University
Innovative Cellular Therapeutics Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
A prospective study to evaluate the safety and efficacy of CART19 for refractory/relapsed B cell lymphoma.
Timeline
- Start
- 2017-04-05
- Primary completion
- 2018-12-31
- Completion
- 2020-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tisagenlecleucel | Cell therapy | — | — |